TYL:NYSETyler Technologies, Inc. Analysis
Data as of 2026-05-28 - not real-time
$302.55
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Tyler Technologies posted a Q1 2026 earnings beat, delivering record revenue and stronger free‑cash flow than analysts expected. The company’s revenue grew 8.6% year‑over‑year, and forward EPS is projected to double, highlighting robust growth momentum. Technically, the stock trades at $302.55, sitting below its 20‑day (≈$319) and 50‑day (≈$330) simple moving averages, indicating a short‑term bearish bias. The 14‑day RSI of 39 suggests the shares are approaching oversold territory, while the MACD histogram remains negative, reinforcing downside pressure. Volume has been decreasing, and the price is hovering just above the identified support level of $294, leaving limited downside cushion. Despite the bearish technical backdrop, analysts collectively rate the stock as a “buy” with a median target of $440, implying a ~45% upside from current levels.
However, the DCF‑derived fair value of roughly $258 places the market price in overvalued territory, and the forward P/E of 21, though lower than the trailing 42, still exceeds the industry average of 40. The company’s balance sheet is strong, featuring ample cash ($346 M) and modest debt, and its low beta (~0.3) points to limited systematic risk. The recent upsized $1.44 B convertible senior notes offering provides additional liquidity for strategic initiatives, such as expanding its SaaS platform and deepening the AWS partnership. With a volatility of nearly 40% over the past 30 days and a sector classified as medium‑risk, investors should weigh the growth upside against the current price premium. Given the combination of solid fundamentals, public‑sector contract stability, and a clear roadmap toward SaaS acceleration, the long‑run outlook remains positive. In the near term, the stock may test its support before any rebound, but the earnings beat and upside‑oriented analyst coverage suggest a potential reversal once technical pressure eases.
However, the DCF‑derived fair value of roughly $258 places the market price in overvalued territory, and the forward P/E of 21, though lower than the trailing 42, still exceeds the industry average of 40. The company’s balance sheet is strong, featuring ample cash ($346 M) and modest debt, and its low beta (~0.3) points to limited systematic risk. The recent upsized $1.44 B convertible senior notes offering provides additional liquidity for strategic initiatives, such as expanding its SaaS platform and deepening the AWS partnership. With a volatility of nearly 40% over the past 30 days and a sector classified as medium‑risk, investors should weigh the growth upside against the current price premium. Given the combination of solid fundamentals, public‑sector contract stability, and a clear roadmap toward SaaS acceleration, the long‑run outlook remains positive. In the near term, the stock may test its support before any rebound, but the earnings beat and upside‑oriented analyst coverage suggest a potential reversal once technical pressure eases.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish technical indicators (price below SMA20/50, negative MACD)
- Proximity to near‑term support at $294
- Recent earnings beat providing short‑term cushion
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Strong revenue growth and expanding free cash flow
- Analyst consensus target price ~45% above current level
- Upsized convertible notes enhancing liquidity for growth initiatives
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Durable public‑sector contract base and SaaS momentum
- Strategic partnership with AWS for cloud services
- Solid balance sheet with low leverage and ample cash
Key Metrics & Analysis
Financial Health
Revenue Growth8.60%
Profit Margin13.26%
P/E Ratio42.4
ROE8.93%
ROA4.68%
Debt/Equity1.35
P/B Ratio3.5
Op. Cash Flow$704.6M
Free Cash Flow$544.5M
Industry P/E40.4
Technical Analysis
TrendBearish
RSI39.1
Support$294.36
Resistance$366.63
MA 20$319.41
MA 50$330.45
MA 200$428.99
MACDBearish
VolumeDecreasing
Fear & Greed Index92.34
Valuation
Fair Value$257.78
Target Price$445.14
Upside/Downside47.13%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.32
Volatility39.67%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.